Literature DB >> 9196696

Parkinson's disease.

J R Playfer1.   

Abstract

Parkinson's disease is a common disabling disease of old age. The diagnosis of idiopathic Parkinson's disease is based on clinical signs and has poor sensitivity, with about 25% of patients confidently diagnosed as having the disease actually having other conditions such as multi-system atrophy and other parkinsonism-plus syndromes. Benign essential tremor and arteriosclerotic pseudo-parkinsonism can easily be confused with Parkinson's disease. The cause of Parkinson's disease remains unknown. Speculative research highlights the role of oxidative stress and free radical mediated damage to dopaminergic cells. Parkinson's disease is the one neurodegenerative disorder in which drugs have been demonstrated to be of value. There is now a wide variety of drugs and formulations available, including anticholinergics, amantidine, L-dopa, dopamine agonists including apomorphine, selegiline and soon to be available catechol-O-methyltransferase inhibitors. Disabling side-effects of treatment, fluctuations, dyskinesias and psychiatric problems require strategic use of the drugs available. There is an increasing potential for neurosurgical intervention.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9196696      PMCID: PMC2431321          DOI: 10.1136/pgmj.73.859.257

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  19 in total

Review 1.  Parkinsonism--recognition and differential diagnosis.

Authors:  N Quinn
Journal:  BMJ       Date:  1995-02-18

Review 2.  Drug treatment of Parkinson's disease.

Authors:  N Quinn
Journal:  BMJ       Date:  1995-03-04

3.  Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.

Authors:  P Limousin; P Pollak; C L Gervason-Tournier; M Hommel; J E Perret
Journal:  Lancet       Date:  1993-06-19       Impact factor: 79.321

Review 4.  Cellular pathology of multiple system atrophy: a review.

Authors:  P L Lantos; M I Papp
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

5.  Parkinson's disease in 65 pairs of twins and in a set of quadruplets.

Authors:  C D Ward; R C Duvoisin; S E Ince; J D Nutt; R Eldridge; D B Calne
Journal:  Neurology       Date:  1983-07       Impact factor: 9.910

6.  Evidence to support early levodopa therapy in Parkinson disease.

Authors:  C H Markham; S G Diamond
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

7.  Tremor, the cogwheel phenomenon and clonus in Parkinson's disease.

Authors:  L J Findley; M A Gresty; G M Halmagyi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-06       Impact factor: 10.154

8.  Routine outpatient L-dopa monitoring in elderly patients with Parkinson's disease.

Authors:  L G Copeland; J Dutton; N B Roberts; J R Playfer
Journal:  Age Ageing       Date:  1994-03       Impact factor: 10.668

9.  Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

Authors:  M Merello; A J Lees; R Webster; M Bovingdon; A Gordin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

10.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

Authors:  A J Lees
Journal:  BMJ       Date:  1995-12-16
View more
  1 in total

Review 1.  Experimental Intrastriatal Applications of Botulinum Neurotoxin-A: A Review.

Authors:  Alexander Hawlitschka; Andreas Wree
Journal:  Int J Mol Sci       Date:  2018-05-07       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.